

Highlights of This Issue 5369

SPECIAL FEATURES

CCR Translations

- 5371 | **Highly Active Antitumor Therapy (HAAT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer**
Juliann Chmielecki and William Pao
See article p. 5489

Molecular Pathways

- 5374 | **Target of Rapamycin Signaling in Leukemia and Lymphoma**
Collin Vu and David A. Fruman

Special Report

- 5381 | **Phase III Clinical Trial Development: A Process of Chutes and Ladders**
David M. Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, and James H. Doroshow
See article p. 5557

HUMAN CANCER BIOLOGY

- 5390 | **Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene *CADM-2* in Human Prostate Cancer**
Guimin Chang, Shuping Xu, Rajiv Dhir, Uma Chandran, Denise S. O'Keefe, Norman M. Greenberg, and Jeffrey R. Gingrich
- 5402 | **MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer**
María Dolores Giráldez, Francesc Balaguer, Luis Bujanda, Miriam Cuatrecasas, Jenifer Muñoz, Virginia Alonso-Espinaco, Mikel Larzabal, Anna Petit, Victoria Gonzalo, Teresa Ocaña, Leticia Moreira, José María Enríquez-Navascués, C. Richard Boland, Ajay Goel, Antoni Castells, and Sergi Castellví-Bel

- 5414 | **Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect**

Michael C. Risk, Beatrice S. Knudsen, Ilsa Coleman, Ruth F. Dumpit, Alan R. Kristal, Nolwenn LeMeur, Robert C. Gentleman, Lawrence D. True, Peter S. Nelson, and Daniel W. Lin

CANCER THERAPY: PRECLINICAL

- 5424 | **Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia**

Nicolas Chapuis, Jerome Tamburini, Alexa S. Green, Christine Vignon, Valerie Bardet, Aymeric Neyret, Melanie Pannetier, Lise Willems, Sophie Park, Alexandre Macone, Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Herault, Catherine Lacombe, Patrick Mayeux, and Didier Bouscary

- 5436 | **The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models**

Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik Choon Tan, Andrew Thorburn, and Stephen Leong

- 5447 | **Development of a Validated Immunofluorescence Assay for γ H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity**

Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, and James H. Doroshow; for the National Cancer Institute Phase 0 Clinical Trials Team

- 5458 **Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses**
Weiyi Peng, Yang Ye, Brian A. Rabinovich, Chengwen Liu, Yanyan Lou, Minying Zhang, Mayra Whittington, Yan Yang, Willem W. Overwijk, Gregory Lizée, and Patrick Hwu
- 5469 **Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models**
Ansgar Santel, Manuela Aleku, Nadine Röder, Kristin Möpert, Birgit Durieux, Oliver Janke, Oliver Keil, Jens Endruschat, Sibylle Dames, Christian Lange, Mona Eisermann, Kathrin Löffler, Melanie Fechtner, Gerald Fisch, Christiane Vank, Ute Schaeper, Klaus Giese, and Jörg Kaufmann
- 5481 **Eradication of Medullary Multiple Myeloma by CD4⁺ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen**
Robbert M. Spaapen, Richard W.J. Groen, Kelly van den Oudenalder, Teun Guichelaar, Maureen van Elk, Tineke Aarts-Riemens, Andries C. Bloem, Gert Storm, Anton C. Martens, Henk M. Lokhorst, and Tuna Mutis
- 5489 **Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer**
Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, and Tetsuya Mitsudomi
See commentary p. 5371
- 5499 **Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia**
Chengzhi Xie, Holly Edwards, Xuelian Xu, Hui Zhou, Steven A. Buck, Mark L. Stout, Qun Yu, Jeffrey E. Rubnitz, Larry H. Matherly, Jeffrey W. Taub, and Yubin Ge

IMAGING, DIAGNOSIS, PROGNOSIS

- 5511 **Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma**
Jung-Hee Kwon, Jongmin Kim, Jin Young Park, Sun Mi Hong, Chang Wook Park, Seok Joo Hong, Sun Young Park, Yoon Jung Choi, In-Gu Do, Jae-Won Joh, Dae Shick Kim, and Kwan Yong Choi
- 5522 **Prognostic Significance of RNA-Dependent Protein Kinase on Non-Small Cell Lung Cancer Patients**
Abujiang Pataer, Maria Gabriela Raso, Arlene M. Correa, Carmen Behrens, Koji Tsuta, Luisa Solis, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba, and Stephen G. Swisher
- 5529 **Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma**
Lydia Kriegl, Andreas Jung, Jutta Engel, Rene Jackstadt, Alexander L. Gerbes, Eike Gallmeier, Jana A. Reiche, Heiko Hermeking, Antonia Rizzani, Christiane J. Bruns, Frank T. Kolligs, Thomas Kirchner, Burkhard Göke, and Enrico N. De Toni

CANCER THERAPY: CLINICAL

- 5539 **Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study**
Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Easty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, and Richard Harrop
- 5548 **A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival**
Richard J. Barth, Jr., Dawn A. Fisher, Paul K. Wallace, Jacqueline Y. Channon, Randolph J. Noelle, Jiang Gui, and Marc S. Ernstoff


- 5557 **A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies**
Steven K. Cheng, Mary S. Dietrich, and David M. Dilts
See commentary p. 5381
- 5564 **REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer**
Charles Comins, James Spicer, Andrew Protheroe, Victoria Roulstone, Katie Twigger, Christine M. White, Richard Vile, Alan Melcher, Matt C. Coffey, Karl L. Mettinger, Gerard Nuovo, David E. Cohn, Mitch Phelps, Kevin J. Harrington, and Hardev S. Pandha
- 5573 **Combination of Temozolomide (TMZ) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks**
Jann N. Sarkaria, Eva Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence Doyle, Caterina Giannini, Kurt A. Jaeckle, and Jan C. Buckner

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 5581 **Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment**
D. Ross Camidge, Scott A. Kono, Antonella Flacco, Aik-Choon Tan, Robert C. Doebele, Qing Zhou, Lucio Crino, Wilbur A. Franklin, and Marileila Varela-Garcia
- 5591 **Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients**
Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, and Heinz-Josef Lenz

ABOUT THE COVER

Atu027, a liposomal siRNA, is a novel RNAi therapeutic for cancer therapy suppressing PKN3 gene expression in endothelial cells of the vasculature. In cultured human endothelial cells (HUVEC), Atu027 mediated downregulation of PKN3 led to increased levels of the adhesion protein vascular endothelial (VE)-cadherin. The different levels of VE-cadherin protein are depicted in this image in a color-coded manner reflecting highest VE-cadherin levels as red colored membrane staining. The authors show that Atu027 treatment modulates the vascular endothelium in a way that metastasis through the blood vessels to the lung is effectively inhibited. For further details, please see Santel and colleagues on page 5469 in this issue.



Clinical Cancer Research

16 (22)

Clin Cancer Res 2010;16:5369-5602.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/22>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/22>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.